Active Ingredient History

NOW
  • Now
Samarium SM-153 lexidronam is a chelated complex of a radioisotope of the element samarium with ethylenediamine tetra(methylene phosphonic acid) (EDTMP). Samarium Sm-153 EDTMP has an affinity for bone and concentrates in areas of bone turnover in association with hydroxyapatite. In clinical studies employing planar imaging techniques, more Samarium (153Sm) lexidronam accumulates in osteoblastic lesions than in normal bone with a lesion-to-normal bone ratio of approximately 5. It is indicated for the relief of pain in patients with confirmed osteoblastic metastatic bone lesions that enhance on radionuclide bone scan. It should not be given concurrently with chemotherapy or external beam radiation therapy unless the benefit outweighs the risks. The most common adverse events are: nausea and vomiting, hemoglobin decrease, myasthenia, paresthesia, thrombocytopenia and abdominal pain.   NCATS

More Chemistry
  • Mechanisms of Action: Missing data
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: No
153sm | samarium 153 | samarium-153 | samarium sm153 | samarium sm-153 | sm-153

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue